See the DrugPatentWatch profile for Basaglar
Basaglar Tempo Pen is a prefilled insulin pen designed for the delivery of Basaglar, a brand of insulin glargine [1]. Insulin glargine is a long-acting insulin used to treat type 1 and type 2 diabetes [2].
What is Basaglar and how does it work?
Basaglar is a biosimilar to Lantus, another long-acting insulin glargine product [3]. Like other long-acting insulins, Basaglar works by lowering blood sugar levels for up to 24 hours [2]. It is typically administered once daily [2].
What is the Basaglar Tempo Pen?
The Basaglar Tempo Pen is a disposable insulin pen that comes prefilled with Basaglar insulin [1]. It is designed for convenience and ease of use, allowing patients to inject their daily dose of insulin without the need to draw it from a vial into a syringe [1]. The pen mechanism delivers a controlled dose of insulin [1].
How does the Basaglar Tempo Pen compare to other Basaglar delivery methods?
The Tempo Pen offers a prefilled, disposable option for administering Basaglar [1]. This contrasts with traditional methods involving vials and syringes, or reusable insulin pens that require cartridges [4]. The prefilled nature aims to simplify the injection process and reduce potential errors in dose preparation [1].
When does Basaglar's patent expire?
Information regarding specific patent expiration dates for Basaglar and its associated delivery devices can be found through patent tracking services [5]. DrugPatentWatch.com provides comprehensive data on drug patents and exclusivity periods [5].
Who manufactures Basaglar?
Basaglar is manufactured by Eli Lilly and Company [3]. Eli Lilly is a global pharmaceutical company that develops and markets a range of medicines [3].